Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and early clinical literature
PubMed 42124049 · doi:10.3390/nu18091444
What was done
This narrative review synthesized preclinical and clinical evidence regarding sulforaphane in cutaneous disorders and skin injury, including UV-induced damage, photoaging, atopic dermatitis, psoriasis, acne vulgaris, and rosacea. It evaluated molecular mechanisms (predominantly Keap1/Nrf2 and NF-κB pathways) and translational constraints related to delivery, formulation, and dosing.
What was found
The abstract reports no quantitative values or effect estimates. The review notes that sulforaphane reduces markers of cutaneous damage, erythema, and edema in preclinical models and limited human data. The strongest available human evidence supports UV-associated skin outcomes and photoprotection, while robust human efficacy data are lacking for chronic inflammatory dermatoses.
Why it matters
The paper clarifies that despite strong preclinical antioxidant and anti-inflammatory signaling mechanisms, sulforaphane remains an early-stage translational candidate lacking robust clinical trial support for common dermatological diseases.
Limits
The abstract describes a narrative rather than a systematic review. Most findings are derived from cell culture and animal models that do not fully model human skin diseases. Human data are limited, unstandardized in dosing and formulation, and largely absent for chronic inflammatory conditions.
Cited by
- contradicts Sulforaphane activates the Nrf2 pathway in skin cells, helping to treat acne.